Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
1997 2
1998 2
1999 2
2000 6
2001 9
2002 7
2003 10
2004 10
2005 11
2006 10
2007 11
2008 3
2009 12
2010 9
2011 15
2012 18
2013 25
2014 27
2015 25
2016 24
2017 34
2018 35
2019 51
2020 79
2021 106
2022 101
2023 107

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Results by year

Filters applied: . Clear all
Page 1
Breast cancer.
Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Loibl S, et al. Among authors: curigliano g. Lancet. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1. Lancet. 2021. PMID: 33812473 Review.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: curigliano g. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M; Panelists of the St Gallen Consensus Conference. Burstein HJ, et al. Among authors: curigliano g. Ann Oncol. 2021 Oct;32(10):1216-1235. doi: 10.1016/j.annonc.2021.06.023. Epub 2021 Jul 6. Ann Oncol. 2021. PMID: 34242744 Free PMC article. Review.
HER2-Low Breast Cancer: Pathological and Clinical Landscape.
Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G. Tarantino P, et al. Among authors: curigliano g. J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. J Clin Oncol. 2020. PMID: 32330069 Review. No abstract available.
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G. Tarantino P, et al. Among authors: curigliano g. CA Cancer J Clin. 2022 Mar;72(2):165-182. doi: 10.3322/caac.21705. Epub 2021 Nov 12. CA Cancer J Clin. 2022. PMID: 34767258 Free article. Review.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Hurvitz SA, et al. Among authors: curigliano g. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495879 Free article. Clinical Trial.
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gennari A, et al. Among authors: curigliano g. Ann Oncol. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19. Ann Oncol. 2021. PMID: 34678411 Free article. No abstract available.
Bystander effect of antibody-drug conjugates: fact or fiction?
Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Giugliano F, et al. Among authors: curigliano g. Curr Oncol Rep. 2022 Jul;24(7):809-817. doi: 10.1007/s11912-022-01266-4. Epub 2022 Mar 19. Curr Oncol Rep. 2022. PMID: 35305211 Review.
Targeting brain metastases in breast cancer.
Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Corti C, et al. Among authors: curigliano g. Cancer Treat Rev. 2022 Feb;103:102324. doi: 10.1016/j.ctrv.2021.102324. Epub 2021 Dec 16. Cancer Treat Rev. 2022. PMID: 34953200 Review.
689 results